The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tarasova L.V.

Surgut State University;
I.N. Ulyanov Chuvash State University;
Surgut District Clinical Hospital

Busalaeva E.I.

Institute for Advanced Medical Studies;
I.N. Ulyanov Chuvash State University

Tsyganova Yu.V.

I.N. Ulyanov Chuvash State University

Zhudtlina N.V.

Surgut District Clinical Hospital

Matysyakevich I.D.

Surgut District Clinical Hospital

Vedolizumab in ulcerative colitis: clinical case

Authors:

Tarasova L.V., Busalaeva E.I., Tsyganova Yu.V., Zhudtlina N.V., Matysyakevich I.D.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2020;9(3): 77‑82

DOI: 10.17116/dokgastro2020903177

Read: 16503 times

Download PDF (RU)
Contact the author
Table of contents

VEDOLIZUMAB IN ULCERATIVE COLITIS: CLINICAL CASE
VEDOLIZUMAB IN ULCERATIVE COLITIS: CLINICAL CASE

To cite this article:

Tarasova LV, Busalaeva EI, Tsyganova YuV, Zhudtlina NV, Matysyakevich ID. Vedolizumab in ulcerative colitis: clinical case. Russian Journal of Evidence-Based Gastroenterology. 2020;9(3):77‑82. (In Russ.)
https://doi.org/10.17116/dokgastro2020903177

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnostic significance of the gut microbiota and its meta­bolites in cardiovascular risk asse­ssment among patients with ulce­rative coli­tis. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):39-46
Tube­rculous otitis media in an adolescent. Clinical case. Russian Bulletin of Otorhinolaryngology. 2024;(5):63-66
Comparative analysis of the resu­lts of treatment of gastric polyps by methods of loop electroexcision, laser and endo­scopic poly­pectomy with aspi­ration capture. Endo­scopic Surgery. 2024;(6):24-30
Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):709-712
Clinical and epidemiological indi­cators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
Features of orofacial and soma­tic pain mani­festations in patients with Crohn’s disease and ulce­rative coli­tis. Russian Journal of Pain. 2025;(1):10-15
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Abstract:

Clinical case of severe steroid-dependent ulcerative colitis with complications of immunosuppressive therapy and basic treatment inefficacy is described. This clinical case demonstrates the possibility of achieving clinical remission in patients with ulcerative colitis with a complex medical history.

Keywords:

vedolizumab
entivio
ulcerative colitis
treatment

Authors:

Tarasova L.V.

Surgut State University;
I.N. Ulyanov Chuvash State University;
Surgut District Clinical Hospital

Busalaeva E.I.

Institute for Advanced Medical Studies;
I.N. Ulyanov Chuvash State University

Tsyganova Yu.V.

I.N. Ulyanov Chuvash State University

Zhudtlina N.V.

Surgut District Clinical Hospital

Matysyakevich I.D.

Surgut District Clinical Hospital

Received:

11.06.2020

Accepted:

24.06.2020

Close metadata

References:

  1. Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL. Respiratory Tract Infections in Patients with Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. Journal of Crohn’s and Colitis. 2018;12(8):905-919.  https://doi.org/10.1093/ecco-jcc/jjy047
  2. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839-851.  https://doi.org/10.1136/gutjnl-2015-311079
  3. Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clinical Pharmacokinetics. 2017;56(11):1287-1301. https://doi.org/10.1007/s40262-017-0546-0
  4. Ivashkin VT, Shelygin YuA, Khalif IL, Belousova EA, Shifrin OS Abdulganieva DI, Abdulkhakov RA, Alekseeva OP, Alekseenko SA, Achkasov SI, Baranovsky AYu, Bolikhov KV, Valujskikh EYu, Vardanyan AV, Veselov AV, Veselov VV, Golovenko AO, Golovenko OV, Grigoriev EG, Gubonina IV, Zhigalova TN, Kashnikov VN, Kizova EA, Knyazev OV, Kostenko NV, Kulyapin AV, Morozova NA, Muraviev AV, Nizov AA, Nikitina NV, Nikolaeva NN, Nikulina NV, Odintsova AKh, Osipenko MF, Pavlenko VV, Parfenov AI, Poluektova EA, Potapov AS, Rumyantsev VG, Svetlova IO, Sitkin SI, Timerbulatov VM, Tkachev AV, Tkachenko EI, Frolov SA, Khubezov DA, Chashkova EYu, Shapina MV, Shchukina OB, Yakovlev AA. Klinicheskie rekomendatsii Rossijskoj gastroenterologicheskoj assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu yazvennogo kolita. Koloproktologiya. 2017;1(59):6-30. (In Russ.)
  5. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2014;8:443-468.  https://doi.org/10.1016/j.crohns.2013.12.013
  6. Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. Journal of Gastroenterogy. 2018;5:585-590.  https://doi.org/10.1007/s00535-018-1449-z
  7. Borisov SE, Lukina GV. Rekomendatsii po skriningu i monitoringu tuberkuleznoj infektsii u bol’nykh, poluchayushchikh genno-inzhenernye biologicheskie preparaty. Accessed April 20, 2020. (In Russ.) https://www.rheumatolog.ru
  8. Stepashina TE, Tarasova LV, Busalaeva EI. The effectiveness of golimumab in severe ulcerative colitis with extraintestinal manifestations. Eksperimental’naya i klinicheskaya gastroenterologiya. 2015;12(124):116-119. (In Russ.)
  9. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Remikade. Registratsionnyj nomer П N012948/01. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
  10. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Humira. Registratsionnyj nomer ЛС-002422-200814. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
  11. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Entivio. RU №LP-003697. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
  12. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Simponi. Registratsionnyj nomer LP-003825. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
  13. Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimization. Alimentary Pharmacology and Therapeutics. 2019; 49(4):408-418.  https://doi.org/10.1111/apt.15113
  14. Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11(10): e0165435. https://doi.org/10.1371/journal.pone.0165435
  15. Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases. 2018;24(11):2431-2441. https://doi.org/10.1093/ibd/izy153
  16. Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World Journal of Gastroenterology. 2018;24(23):2457-2467. https://doi.org/10.3748/wjg.v24.i23.2457
  17. Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D’Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M.Jr. Long-term efficacy of vedolizumab for ulcerative colitis. Journal of Crohn’s and Colitis. 2017;11(4):400-411.  https://doi.org/10.1093/ecco-jcc/jjw177
  18. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.  https://doi.org/10.1053/j.gastro.2008.01.012
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.